Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2004, p. 5080-5087, Vol. 24, No. 11
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.11.5080-5087.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Division of Signal Transduction, Beth Israel Deaconess Medical Center, and Department of Cell Biology, Harvard Medical School,1 Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, and Department of Medicine, Harvard Medical School, Boston,2 Boston Biomedical Research Institute, Watertown, Massachusetts3
Received 25 November 2003/ Returned for modification 5 January 2004/ Accepted 16 March 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although many molecules have been implicated in insulin signaling in ex vivo or in in vitro systems, relatively few have been shown to affect glucose homeostasis in vivo (22). Not surprisingly, genetic disruption of the insulin receptor or insulin receptor substrates (e.g., IRS-1) has been shown to reduce whole-body insulin responsiveness (2, 3, 30). In addition, mice lacking protein tyrosine phosphatase 1B, which dephosphorylates the insulin receptor and insulin receptor substrates (15), are lean and have enhanced insulin sensitivity in vivo (13, 20). Also, genetic manipulation of the phosphoinositide 3-kinase (PI3K) signaling pathway in mice has been shown to affect insulin sensitivity. Mice with reduced levels of p85 regulatory subunits of PI3K (which can exert a negative effect on the pathway) have increased insulin sensitivity (14, 23, 31, 33). Deletion of Akt2, a protein serine/threonine kinase that is activated by the PI3K-generated second messenger phosphatidylinositol 3,4,5-tris-phosphate (PI-3,4,5-P3), results in impaired insulin signaling in mice (10). Finally, disruption of the gene encoding SHIP2, a phosphatase that degrades PI-3,4,5-P3, results in a dramatic increase in insulin sensitivity in mice (11).
Aberrant regulation of other phosphoinositides, such as phosphatidylinositol 4,5-bis-phosphate (PI-4,5-P2), may contribute to diabetes and obesity. For example, PI-4,5-P2 is the substrate used by PI3K for synthesis of PI-3,4,5-P3. In addition, PI-4,5-P2 regulates the function of the Tubby protein. Mice with mutations in the tubby gene develop maturity-onset obesity and diabetes (6, 28).
The bulk of PI-4,5-P2 in mammalian cells is synthesized from phosphatidylinositol 4-phosphate (PI-4-P) (35). A few years ago, it was shown that the type II phosphatidylinositol phosphate kinases produce PI-4,5-P2 by an alternative route, namely, via phosphatidylinositol 5-phosphate (PI-5-P) (26), and they are now called phosphatidylinositol 5-phosphate 4-kinases (PI-5-P4-kinases). PI-5-P is far less abundant than PI-4-P or PI-4,5-P2, and relatively little is known about its function or regulation. Some recent results indicate a role for PI-5-P in the regulation of PI3-kinase signaling: two groups demonstrated that the bacterial phosphatase IpgD, which was previously known to be required for Akt activation upon invasion, is a lipid phosphatase that produces PI-5-P from PI-4,5-P2 (21, 25, 29, 32). Mammals have three isoforms of PI-5-P 4-kinase (PI5P4K
, PI5P4Kß, and PI5P4K
) encoded by distinct genes (9, 12, 17), and it was recently shown that overexpression of any of these three enzymes diminishes the insulin-stimulated activation of Akt by reducing the amount of PI-3,4,5-P3 produced after insulin stimulation (8). These enzymes have different but overlapping tissue distributions. To assess the physiological importance of PI5P4Kß, we generated mice lacking this protein. PI5P4Kß/ mice were found to have increased insulin sensitivity, reduced growth rates, and lower fat content than wild-type littermates. The observed insulin hypersensitivity is consistent with a role for the PI-5-P pathway in regulating PI 3-kinase signaling downstream of the insulin receptor.
| MATERIALS AND METHODS |
|---|
|
|
|---|
PCR. For genotyping, a set of three primers was used to amplify regions of genomic DNA present in either wild-type samples or knockout samples. We used a single antisense primer (pR: ACC ATC CCA AAG CAC CCA GGA CC) corresponding to intron sequence downstream of the insertion site and two sense primers, one corresponding to intron sequence upstream of the insertion (pwtF: CGT GCT ATG CCG TCG TCG TTT CC) and the other within the 3' end of the Lexicon insertion (pkoF: AGA AGC GAG AAG CGA ACT GAT TGG). The primer pair pwtF/pR amplifies a fragment of 598 bp, and the primer pair pkoF/pR amplifies a fragment of 496 bp. We used the recommended cycling conditions for Perkin Elmer AmpliTaq Gold with an annealing temperature of 56°C.
RT-PCR. cDNA derived from the endogenous PI5P4Kß transcript was prepared by using a primer complementary to 29 bases in exon VIII of PI5P4Kß (5'-CCT CGT CCT CTG CCC GCT CCT CCA CCT CC-3'). A fragment corresponding to bases 51 to 902 of the endogenous coding sequence was amplified using a forward primer from exon I (5'-CGC CAG CAA GAC AAG ACC AAG AAG AAG-3') and a reverse primer to exon VIII (5'-CGC TCC TCC ACC TCC ATC TCC TCC-3').
cDNA derived from the hybrid transcript produced by splicing the first exon of PI5P4Kß to the 5' cassette of the Lexicon retroviral insertion vector was prepared with a primer complementary to the ßgeo sequence within the Lexicon vector. A fragment from the hybrid transcript was amplified with the forward primer from exon I (described above) and a nested reverse primer from the ßgeo sequence in the Lexicon insertion vector (5'-GCA TCC TTC AGC CCC TTG TTG-3').
Production of PI5P4Kß antibody.
PI5P4Kß was cloned into the pGEX-4T-2 bacterial glutathione S-transferase fusion expression vector. GST-PI5P4Kß was expressed in Escherichia coli strain DH5
, purified on glutathione-agarose beads, and cleaved with 2.5 U of thrombin (Sigma product no. T6634) per mg of fusion protein. Thrombin was removed from the solution by incubation with 20 µl of p-aminobenzamidine agarose beads (Sigma product no. A7155). Soluble, cleaved PI5P4Kß was injected into rabbits at Pocono Rabbit Farm and Laboratory for antibody production. Anti-PI5P4Kß antibodies were purified from 10 ml of rabbit serum on a column of untagged bacterially expressed PI5P4Kß covalently attached to CNBr-activated Sepharose (Sigma product no. C9142).
Tissue lysate preparation and Western blotting. Tissue lysates were prepared by homogenizing tissues flash frozen in liquid nitrogen with a Tissue Tearor homogenizer in 400 to 750 µl of ice-cold buffer containing 50 mM HEPES (pH 7.4), 138 mM KCl, 4 mM NaCl, 1% NP-40, 50 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium orthovanadate, protease inhibitor pellets (Roche product no. 1873580), and 1 mM phenylmethylsulfonyl fluoride. After homogenization, the samples were incubated for 1 to 4 h at 4°C and then centrifuged for 10 min at 16,000 x g. Protein concentrations in lysates from adipose tissues were determined by subjecting an aliquot to precipitation by 10% trichloroacetic acid. Protein concentrations in other tissue lysates were determined by the Lowry method. For Western blotting, 40 to 100 µg of total protein was loaded per lane.
In vivo insulin stimulation. Either saline control or 0.5 U of Novolin-R per kilogram of body weight was administered to 5-month-old female mice by tail vein injection. The mice were sacrificed by cervical dislocation 5 min after the injection of saline or insulin and quickly dissected, and the tissues were flash frozen in liquid nitrogen.
Akt activity assays.
Akt protein was immunoprecipitated from 500 µg of total lysate by incubation with 2 µg of an anti-Akt polyclonal antibody that recognizes both Akt1 and Akt2 (Upstate Biotechnology) coupled to protein G Sepharose for 4 h at 4°C. The immune pellets were washed three times in buffer containing 20 mM Tris (pH 7.5), 5 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 2 mM Na3VO4 and 1% NP-40 and then twice in 50 mM Tris (pH 7.5), 10 mM MgCl2, and 1 mM dithiothreitol. The beads were resuspended in 50 µl of kinase mixture (50 mM Tris [pH 7.5], 10 mM MgCl2, 1 mM dithiothreitol, 5 µM ATP, 1 µM protein kinase inhibitor, 30 µM Crosstide (peptide substrate for Akt), and 2 µCi of [
-32P]ATP) and incubated for 30 min at 30°C. Samples (40 µl) were spotted onto phosphocellulose p81 paper and washed four times with 75 mM orthophosphoric acid and once with acetone. Radioactivity incorporation was determined by scintillation counting.
Weight measurements. Mice were weighed daily between the ages of 9 and 21 days, every 3 days between the ages of 21 and 54 days, and weekly between the ages of 8 and 26 weeks.
Insulin tolerance tests. Mice were placed in clean cages (without food) at 9:00 a.m. and were injected intraperitoneally at 1:00 p.m. on the same day with Novolin-R at a dosage of 0.5 to 0.75 U per kg of body weight. Blood glucose was measured with a One Touch Basic glucose meter before injection of insulin and at 15, 30, 45, 60, and 90 min following insulin injection.
Glucose tolerance tests. Mice were placed in clean cages (without food) at 7:00 p.m. on the day prior to the experiment. At 9:00 a.m. the following day, the mice were injected with 1 mg of glucose per g of body weight from a 20-mg/ml solution of glucose in 0.9% NaCl (autoclaved and filtered). Blood glucose levels were measured with a One Touch Basic glucose meter before the injection of glucose and at 10, 20, 30, 60, 120, and 180 min following glucose injection.
Body composition analysis. Mice were euthanized by CO2 asphyxiation, and the stomach and intestines were removed with care to leave the attached fat behind. The wet carcasses were weighed and then dried for 3 to 10 days in a ventilated 60°C oven. The fully dried carcasses (determined by weight stabilization) were placed in a solution of 2 parts ethanol to 1 part 30% potassium hydroxide (KOH) and returned to the 60°C oven for 3 to 10 days, until the carcasses were fully saponified (determined by lack of fat droplets in solution). The carcass lysate volumes were normalized to 100 to 300 ml and analyzed for triglyceride content by using reagent A (Sigma product no. 337-40-A).
Measurement of food intake. Food intake was measured by housing one or two mice of the same genotype per cage and weighing the food in the cages every morning at 9:00 a.m. and every evening at 6:00 p.m. for 2 weeks. The difference between weighings was divided by the number of mice in the cage, and each cage was treated as a single sample for statistical analysis. The amount of food consumed was divided by the average body weight of the mice in each cage to determine the food intake normalized to total body weight.
Insulin and leptin measurements. Serum insulin and serum leptin levels were measured in duplicate or triplicate by using enzyme-linked immunosorbent assay reagents from Crystal Chem Inc. (catalog no. 90060 and 90030).
High-fat diet. Mice were placed on a high-fat diet beginning at the time of weaning (3 weeks of age). We used a synthetic diet prepared by Harlan Teklad (Madison, Wis.; catalog no. TD 93075), which contains 55% fat and 24% carbohydrate by calories.
Statistical analysis. Body weight growth curves, insulin and glucose tolerance tests, and food intake were analyzed by repeated-measures analysis of variance. Body composition, bone lengths, and bone mineral density were analyzed by Student's t test. All analyses were performed with StatView 4.1 software.
| RESULTS |
|---|
|
|
|---|
|
We examined PI5P4Kß protein levels using an anti-PI5P4Kß antibody that we produced. We found PI5P4Kß protein to be absent from all tissues examined from mice homozygous for the Lexicon disruption. We also examined the expression levels of PI5P4K
and PI5P4K
and found that the expression of these genes was not upregulated to compensate for the loss of PI5P4Kß (Fig. 2).
|
|
25% in livers from mice lacking PI5P4Kß compared to wild-type littermates. In contrast, Akt activation in response to insulin in white adipose tissue is not affected by the loss of PI5P4Kß (Fig. 4).
|
|
We found that the spines of male PI5P4Kß/ mice are 5.8% ± 0.3% shorter than those of wild-type littermates (P = 0.004 in the t test) and the femurs of male PI5P4Kß/ mice are 7.3% ± 0.7% shorter than those of wild-type littermates (P = 0.004) at 10 weeks of age. We also found that 10-week-old male PI5P4Kß/ mice have reduced bone mineral density (9.5% ± 0.7% lower than wild type; P = 0.001). This may be a consequence of their reduced body weight. Similar results were obtained for female mice at 10 weeks of age.
We also found that both male and female mice lacking PI5P4Kß had normal amounts of fat at 10 weeks of age but that older PI5P4Kß/ males had significantly less fat tissue than their wild-type littermates. Female PI5P4Kß/ mice had normal amounts of fat at all ages measured, even when they were fed a high-fat diet (Table 1).
|
|
The hormone leptin has been shown to affect both feeding behavior and insulin responsiveness. Because leptin is secreted by fat cells, we measured leptin content in the serum of female mice, which do not have altered body fat composition. We measured the amount of leptin present in serum of wild-type and mutant mice either after an overnight fast or after ad libitum feeding overnight. Leptin levels in PI5P4Kß/ female mice were similar to those of wild-type littermates under both fed and fasting conditions. Furthermore, the leptin levels measured in both wild-type and mutant mice fit a similar linear relationship when compared with the mice's body weights, as expected (Fig. 7).
|
|
| DISCUSSION |
|---|
|
|
|---|
The molecular mechanism by which PI5P4Kß reduces insulin responsiveness is not yet clear. PI-4,5-P2, the product of PI5P4Kß catalytic activity, is a substrate of PI3K for the production of PI-3,4,5-P3. Thus, one might have expected that disruption of PI5P4Kß would decrease insulin signaling, in contrast to what we found. However, it has been shown that overexpression of PI5P 4-kinases in cell culture decreases insulin-dependent Akt phosphorylations (8), which is consistent with our results in PI5P4Kß/ mice. Furthermore, exogenous expression of the bacterial phosphatase IpgD, which produces PI-5-P (25), stimulates the phosphorylation of Akt (8). These results raise the possibility that PI-5-P, the substrate of PI5P4Kß, is required for maintaining PI-3,4,5-P3 levels and Akt activation. Such a model would be consistent with the increased insulin sensitivity and increased Akt activation that we observe in PI5P4Kß/ mice.
PI5P4Kß was originally cloned by association with the 55-kDa tumor necrosis factor receptor (TNFR1) (9). Tumor necrosis factor alpha, a ligand for TNFR1, has been shown to inhibit insulin signaling by an unknown mechanism, possibly involving serine phosphorylation of IRS1 (16, 27). TNFR1/ mice are protected from obesity-induced insulin resistance (34). PI5P4Kß may contribute to signaling downstream of TNFR1 that inhibits insulin response.
The inability of PI5P4K
and PI5P4K
to compensate for the loss of PI5P4Kß in the context of glucose homeostasis in mice may be explained by isoform-specific expression patterns, interaction partners, or subcellular localizations. It appears that a major factor in the insulin hypersensitivity resulting from loss of PI5P4Kß is increased insulin signaling in muscle due to loss of PI5P4Kß in muscle. The ratio of PI5P4Kß expression to PI5P4K
expression is particularly high in skeletal muscle, as seen in Fig. 2. Perhaps the closely related enzyme PI5P4K
is able to compensate more effectively for the loss of PI5P4Kß in tissues in which PI5P4K
is more highly expressed, including white adipose tissue. However, the physiology of glucose homeostasis is controlled by complex communication between multiple tissues, including the brain (1, 4, 5, 18, 19, 24). It would be interesting to examine the isoform-specific and tissue-specific functions of PI-5-P 4-kinases in insulin signaling and glucose homeostasis further by generating mice lacking PI5P4Kß in individual tissues, as well as by generating mice lacking other isoforms of PI-5-P 4-kinase.
Insulin stimulates the transport of glucose into both muscle and fat, where it is metabolized via glycolysis or converted to glycogen or triglycerides, the latter being the major form of adipose tissue accumulation. The increased insulin sensitivity of skeletal muscles in PI5P4Kß/ mice in the presence of normally insulin-responsive adipose tissue would likely lead indirectly to decreased transport of glucose into white adipose tissue because the increased insulin-stimulated glucose transport in muscle leads to a lower requirement for basal insulin secretion, as seen in Fig. 3B. This could explain the reduced adiposity in adult male mice lacking PI5P4Kß. Consistent with this idea, decreased adiposity has also been observed in mice expressing transgenic activated Akt in muscle (David Glass, personal communication).
By measuring bone lengths, we found both male and female PI5P4Kß/ mice to be 5 to 10% shorter than wild-type mice at all ages, probably reflecting slower growth during embryogenesis or in the early postnatal period. The weight difference in male mice increases with age because the growth retardation effect is compounded by decreased fat accumulation in males. The overall growth retardation seems to occur early in life, and inhibition of PI5P4Kß later in life may not affect growth. The non-Mendelian survival of PI5P4Kß/ newborn mice may be related to reduced embryonic growth rates in comparison to those of wild-type mice. Thus far, we have not observed decreased survival in PI5P4Kß/ adult mice. The insulin hypersensitivity, reduced adiposity, and lack of major anatomical or physiological defects observed thus far in adult PI5P4Kß/ mice make PI5P4Kß an attractive target for the development of inhibitors that may be useful in the treatment of obesity and type 2 diabetes.
| ACKNOWLEDGMENTS |
|---|
. We thank Tadaomi Takenawa for sharing an antibody against PI5P4K
. We thank John Watt, Nicole Logsdon, Nikki Madson, and Monica Kosmatka for assistance with breeding and genotyping PI5P4Kß/ mice. We thank Roderick Bronson and Derek Abbott for histological analysis of pancreatic islets. We thank Cyril Benes and Jonathan Hurov for critical reading of the manuscript. This work was supported by NIH grants DK43051, DK60839, and DK57521 to B.B.K. and GM36624 to L.C.C. This investigation was supported by PHS research grant 5 P30 DK36836-15 from the National Institute of Diabetes and Digestive and Kidney Diseases.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Accili, D., J. Drago, E. J. Lee, M. D. Johnson, M. H. Cool, P. Salvatore, L. D. Asico, P. A. Jose, S. I. Taylor, and H. Westphal. 1996. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12:106-109.[CrossRef][Medline]
3. Araki, E., M. A. Lipes, M. E. Patti, J. C. Bruning, B. Haag III, R. S. Johnson, and C. R. Kahn. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190.[CrossRef][Medline]
4. Bluher, M., M. D. Michael, O. D. Peroni, K. Ueki, N. Carter, B. B. Kahn, and C. R. Kahn. 2002. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 3:25-38.[CrossRef][Medline]
5. Bruning, J. C., D. Gautam, D. J. Burks, J. Gillette, M. Schubert, P. C. Orban, R. Klein, W. Krone, D. Muller-Wieland, and C. R. Kahn. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-2125.
6. Cantley, L. C. 2001. Transcription. Translocating tubby. Science 292:2019-2021.
7. Carey, D. G., A. B. Jenkins, L. V. Campbell, J. Freund, and D. J. Chisholm. 1996. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45:633-638.[Abstract]
8. Carricaburu, V., K. A. Lamia, E. Lo, L. Favereaux, B. Payrastre, L. C. Cantley, and L. E. Rameh. 2003. The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation. Proc. Natl. Acad. Sci. USA 100:9867-9872.
9. Castellino, A. M., G. J. Parker, I. V. Boronenkov, R. A. Anderson, and M. V. Chao. 1997. A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and phosphatidylinositol-4-phosphate 5-kinase. J. Biol. Chem. 272:5861-5870.
10. Cho, H., J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw III, K. H. Kaestner, M. S. Bartolomei, G. I. Shulman, and M. J. Birnbaum. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB ß). Science 292:1728-1731.
11. Clement, S., U. Krause, F. Desmedt, J. F. Tanti, J. Behrends, X. Pesesse, T. Sasaki, J. Penninger, M. Doherty, W. Malaisse, J. E. Dumont, Y. Le Marchand-Brustel, C. Erneux, L. Hue, and S. Schurmans. 2001. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409:92-97.[CrossRef][Medline]
12. Divecha, N., O. Truong, J. J. Hsuan, K. A. Hinchliffe, and R. F. Irvine. 1995. The cloning and sequence of the C isoform of PtdIns4P 5-kinase. Biochem. J. 309:715-719.
13. Elchebly, M., P. Payette, E. Michaliszyn, W. Cromlish, S. Collins, A. L. Loy, D. Normandin, A. Cheng, J. Himms-Hagen, C. C. Chan, C. Ramachandran, M. J. Gresser, M. L. Tremblay, and B. P. Kennedy. 1999. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544-1548.
14. Fruman, D. A., F. Mauvais-Jarvis, D. A. Pollard, C. M. Yballe, D. Brazil, R. T. Bronson, C. R. Kahn, and L. C. Cantley. 2000. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 26:379-382.[CrossRef][Medline]
15. Goldstein, B. J., A. Bittner-Kowalczyk, M. F. White, and M. Harbeck. 2000. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J. Biol. Chem. 275:4283-4289.
16. Hotamisligil, G. S., P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-
- and obesity-induced insulin resistance. Science 271:665-668.[Abstract]
17. Itoh, T., T. Ijuin, and T. Takenawa. 1998. A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase II
) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals. J. Biol. Chem. 273:20292-20299.
18. Kim, J. K., A. Zisman, J. J. Fillmore, O. D. Peroni, K. Kotani, P. Perret, H. Zong, J. Dong, C. R. Kahn, B. B. Kahn, and G. I. Shulman. 2001. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin. Investig. 108:153-160.[CrossRef][Medline]
19. Kitamura, T., C. R. Kahn, and D. Accili. 2003. Insulin receptor knockout mice. Annu. Rev. Physiol. 65:313-332.[CrossRef][Medline]
20. Klaman, L. D., O. Boss, O. D. Peroni, J. K. Kim, J. L. Martino, J. M. Zabolotny, N. Moghal, M. Lubkin, Y. B. Kim, A. H. Sharpe, A. Stricker-Krongrad, G. I. Shulman, B. G. Neel, and B. B. Kahn. 2000. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20:5479-5489.
21. Marcus, S. L., M. R. Wenk, O. Steele-Mortimer, and B. B. Finlay. 2001. A synaptojanin-homologous region of Salmonella typhimurium SigD is essential for inositol phosphatase activity and Akt activation. FEBS Lett. 494:201-207.[CrossRef][Medline]
22. Mauvais-Jarvis, F., R. N. Kulkarni, and C. R. Kahn. 2002. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clin. Endocrinol. (Oxford) 57:1-9.[CrossRef][Medline]
23. Mauvais-Jarvis, F., K. Ueki, D. A. Fruman, M. F. Hirshman, K. Sakamoto, L. J. Goodyear, M. Iannacone, D. Accili, L. C. Cantley, and C. R. Kahn. 2002. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J. Clin. Investig. 109:141-149.[CrossRef][Medline]
24. Minokoshi, Y., C. R. Kahn, and B. B. Kahn. 2003. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J. Biol. Chem. 278:33609-33612.
25. Niebuhr, K., S. Giuriato, T. Pedron, D. J. Philpott, F. Gaits, J. Sable, M. P. Sheetz, C. Parsot, P. J. Sansonetti, and B. Payrastre. 2002. Conversion of PtdIns(4,5)P(2) into PtdIns(5)P by the S. flexneri effector IpgD reorganizes host cell morphology. EMBO J. 21:5069-5078.[CrossRef][Medline]
26. Rameh, L. E., K. F. Tolias, B. C. Duckworth, and L. C. Cantley. 1997. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature 390:192-196.[CrossRef][Medline]
27. Rui, L., V. Aguirre, J. K. Kim, G. I. Shulman, A. Lee, A. Corbould, A. Dunaif, and M. F. White. 2001. Insulin/IGF-1 and TNF-
stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Investig. 107:181-189.[CrossRef][Medline]
28. Santagata, S., T. J. Boggon, C. L. Baird, C. A. Gomez, J. Zhao, W. S. Shan, D. G. Myszka, and L. Shapiro. 2001. G-protein signaling through tubby proteins. Science 292:2041-2050.
29. Steele-Mortimer, O., L. A. Knodler, S. L. Marcus, M. P. Scheid, B. Goh, C. G. Pfeifer, V. Duronio, and B. B. Finlay. 2000. Activation of Akt/protein kinase B in epithelial cells by the Salmonella typhimurium effector sigD. J. Biol. Chem. 275:37718-37724.
30. Tamemoto, H., T. Kadowaki, K. Tobe, T. Yagi, H. Sakura, T. Hayakawa, Y. Terauchi, K. Ueki, Y. Kaburagi, S. Satoh, et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186.[CrossRef][Medline]
31. Terauchi, Y., Y. Tsuji, S. Satoh, H. Minoura, K. Murakami, A. Okuno, K. Inukai, T. Asano, Y. Kaburagi, K. Ueki, H. Nakajima, T. Hanafusa, Y. Matsuzawa, H. Sekihara, Y. Yin, J. C. Barrett, H. Oda, T. Ishikawa, Y. Akanuma, I. Komuro, M. Suzuki, K. Yamamura, T. Kodama, H. Suzuki, T. Kadowaki, and et al. 1999. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet 21:230-235.[CrossRef][Medline]
32. Terebiznik, M. R., O. V. Vieira, S. L. Marcus, A. Slade, C. M. Yip, W. S. Trimble, T. Meyer, B. B. Finlay, and S. Grinstein. 2002. Elimination of host cell PtdIns(4,5)P(2) by bacterial SigD promotes membrane fission during invasion by Salmonella. Nat. Cell Biol. 4:766-773.[CrossRef][Medline]
33. Ueki, K., C. M. Yballe, S. M. Brachmann, D. Vicent, J. M. Watt, C. R. Kahn, and L. C. Cantley. 2002. Increased insulin sensitivity in mice lacking p85ß subunit of phosphoinositide 3-kinase. Proc Natl. Acad. Sci. USA 99:419-424.
34. Uysal, K. T., S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-
function. Nature 389:610-614.[CrossRef][Medline]
35. Whiteford, C. C., C. A. Brearley, and E. T. Ulug. 1997. Phosphatidylinositol 3,5-bisphosphate defines a novel PI 3-kinase pathway in resting mouse fibroblasts. Biochem. J. 323:597-601.
36. Zambrowicz, B. P., G. A. Friedrich, E. C. Buxton, S. L. Lilleberg, C. Person, and A. T. Sands. 1998. Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608-611.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|